BIOSURFIT
30.11.2016 09:02:41 CET | Business Wire | Press release
Today, biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces CE Marking (Conformité Européenne ) for its HbA1c (Haemoglobin A1c) test, the third in a series of tests available on its spinit® point-of-care instrument.
The CE Mark approval of the HbA1c clinical chemistry test signifies the latest advancement of biosurfit’s spinit® , the first and only, PoC diagnostic system capable of performing all three of the major blood tests (haematology, immunoassays and clinical chemistry) on the same instrument. The spinit® test could also signal cost-efficiencies for physicians who can now use just one instrument, instead of several ones. Existing, commercially launched tests for the spinit® instrument include CRP (c-reactive protein) and BC (blood count).
The HbA1c test is one of the key diagnostic tests used by physicians to diagnose and monitor diabetes as well as to identify patients at risk of developing diabetes. With a requirement for a tiny finger stick blood sample of only 5µl, the new spinit® clinical chemistry HbA1c test allows physicians to manage the progression of this very serious disease in a few minutes. HbA1c is one of the most commonly used PoC tests performed in physicians’ offices. With the CE marking of biosurfit’s spinit® HbA1c test, biosurfit is now able to offer this valuable tool to help physicians efficiently diagnose and monitor diabetes without having to collect and send blood samples off to a central laboratory.
With the new HbA1c test, along with CRP and Blood cell counting, biosurfit now offers a comprehensive menu of fast, easy to perform laboratory quality tests on the spinit® instrument. The combination of different detection methods on the CD/DVD format of the spinit® disc along with powerful microfluidics will facilitate the development of the pipeline of products in the near future, including a lipid panel, an inflammation panel and a d-dimer test. This attractive menu of tests, on a rapid and simple to use instrument will allow the performance of these key tests in GP offices, clinics, pharmacies and other PoC testing sites.
João Garcia da Fonseca, Chief Executive Officer of biosurfit, commented: “We are delighted to have secured this new and important milestone in the continuous development of spinit® . It is a clear testament to its disruptive, technical viability and rising commercial acceptance in setting the future gold standard in IVD PoC diagnostics. We are looking forward to continuing the roll out and commercialisation of the expanded spinit® test menu in the near future.”
Ian Gilham, Chairman of biosurfit, commented: “CE-Marking of the HbA1c test is a major milestone in the development of the spinit instrument and test menu providing an indispensable aid to patients and physicians in their fight against diabetes. We are excited by the ever expanding menu of spinit tests and the increased installed base of instruments which will be further driven by the launch of new tests and the opening of new global markets in the near future.”
Notes to editors
About biosurfit and spinit ®
biosurfit is a fast-growing and highly innovative commercial stage European medical diagnostics company focused on the development and manufacture of breakthrough technologies for the in vitro diagnostic (IVD) market. Its lead product spinit® , which was commercially launched in 2014, addresses an unmet need for fast, precise, reliable, easy-to-use blood analysis for medical testing in the PoC setting.
1 International Diabetes Federation. IDF Diabetes Atlas, 7th edition, Brussels, Belgium: International Diabetes Federation; http://www.diabetesatlas.org . Accessed 6 November 2016.
2 NIH – National Institute of Diabetes and Digestive and Kidney Diseases: The A1C Test and Diabetes; www.niddk.nih.gov . September 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005156/en/
Contact:
FTI Consulting
(media relations)
Con Franklin
con.franklin@fticonsulting.com
+44
(0)203 727 1000
or
biosurfit SA
João Garcia da
Fonseca, Chief Executive Officer
Daniel Neves, Chief Marketing
Officer / Chief Financial Officer
+351 218 860 169
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Resale on the Rise: Klarna's Resell Feature Grows 75% as Consumers Put Real Money Back in Their Pockets21.4.2026 17:00:00 CEST | Press release
New data from Klarna reveals consumers are making an estimated $137 per sold item as resale becomes a go-to financial habit New data from Klarna,the global digital bank and flexible payments provider, reveals that its in-app resell feature is gaining significant momentum:listings created through the app grew by up to 75% over the past 13 months*, as consumers increasingly turn to resale as a way to earn real money from items they already own. The data points to a broader shift in financial behaviour: consumers are increasingly treating the things they own not as fixed costs, but as assets with ongoing value. Reselling is becoming routine, not a one-off First launched in Sweden in 2022, Klarna's resell feature is now available across 15 markets, letting users list items for resale directly from their purchase history via leading resale marketplaces such as eBay, Poshmark and Tradera. No need to remember what they paid, find the receipt, or switch to another app. Klarna pre-fills key lis
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 16:05:00 CEST | Press release
Training device developed for the Pilatus PC-12 PRO with Garmin’s G3000 PRIME Integrated Flight Deck Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 16:00:00 CEST | Press release
- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details:
Wolters Kluwer CCH Tagetik Kicks Off Global inTouch 2026 Series Showcasing Expert AI in Action for the Office of CFO21.4.2026 15:28:00 CEST | Press release
Wolters Kluwer CCH Tagetik is set to host Global inTouch 2026, its flagship user conference which takes place May 19–21, 2026, in Lucca, Italy. Celebrating its 20th edition, Global inTouch launches a global event series demonstrating how CCH Tagetik with Expert AI is transforming the way finance works with AI-enabled capabilities embedded directly into the processes that matter most to the office of the CFO. Following the event in Lucca, the Global inTouch showcase will continue with regional inTouch events across key markets worldwide, including Belgium, France, Germany, Japan, the Netherlands, Sweden, the United Kingdom, and the United States. This year’s theme, Own the Future, reflects Wolters Kluwer CCH Tagetik’s commitment to continuous innovation and to empowering finance teams to deliver impact today while confidently shaping what’s next. “The role of the CFO is expanding from reporting on the past to strategically orchestrating the future to maximize value creation,” saidMaria
Wasabi Technologies Closes $250M Credit Facility to Expand Cloud Storage Innovation21.4.2026 15:00:00 CEST | Press release
Bain Capital;U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia continue to back storage infrastructure for the AI era Wasabi Technologies, the hot cloud storage company, today announced it has secured a $250 million credit facility led by Bain Capital’s Private Credit Group (“Bain Capital”) with participation from U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia. The financing will support continued investment in Wasabi’s cloud storage platform, infrastructure, and broader global expansion. “This is a more selective private lending market, but we’ve built a strong, disciplined business that continues to attract support from leading financial institutions,” said Michael Bayer, EVP and chief financial officer, Wasabi Technologies. “We’re investing in our infrastructure to meet growing demand for data, es
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom